164 related articles for article (PubMed ID: 35625741)
1. Whole-Exome Sequencing of Germline Variants in Non-
Liu Y; Helgadottir HT; Kharaziha P; Choi J; López-Giráldez F; Mane SM; Höiom V; Juhlin CC; Larsson C; Bajalica-Lagercrantz S
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625741
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
3. The Identification by Exome Sequencing of Candidate Genes in
BenAyed-Guerfali D; Kifagi C; BenKridis-Rejeb W; Ammous-Boukhris N; Ayedi W; Khanfir A; Daoud J; Mokdad-Gargouri R
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893033
[TBL] [Abstract][Full Text] [Related]
4. Identification of known and novel familial cancer genes in Swedish colorectal cancer families.
Helgadottir HT; Thutkawkorapin J; Rohlin A; Nordling M; Lagerstedt-Robinson K; Lindblom A
Int J Cancer; 2021 Aug; 149(3):627-634. PubMed ID: 33729574
[TBL] [Abstract][Full Text] [Related]
5. Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer.
Torrezan GT; de Almeida FGDSR; Figueiredo MCP; Barros BDF; de Paula CAA; Valieris R; de Souza JES; Ramalho RF; da Silva FCC; Ferreira EN; de Nóbrega AF; Felicio PS; Achatz MI; de Souza SJ; Palmero EI; Carraro DM
Front Genet; 2018; 9():161. PubMed ID: 29868112
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract][Full Text] [Related]
8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
9. Exome Sequencing in
Glentis S; Dimopoulos AC; Rouskas K; Ntritsos G; Evangelou E; Narod SA; Mes-Masson AM; Foulkes WD; Rivera B; Tonin PN; Ragoussis J; Dimas AS
Front Genet; 2019; 10():1005. PubMed ID: 31681433
[TBL] [Abstract][Full Text] [Related]
10. Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases.
Hamdi Y; Boujemaa M; Ben Rekaya M; Ben Hamda C; Mighri N; El Benna H; Mejri N; Labidi S; Daoud N; Naouali C; Messaoud O; Chargui M; Ghedira K; Boubaker MS; Mrad R; Boussen H; Abdelhak S;
J Transl Med; 2018 Jun; 16(1):158. PubMed ID: 29879995
[TBL] [Abstract][Full Text] [Related]
11. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
Loveday C; Garrett A; Law P; Hanks S; Poyastro-Pearson E; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Walker L; ; Eccles D; Evans DG; Snape K; Hanson H; Houlston RS; Turnbull C
Ann Oncol; 2022 Dec; 33(12):1318-1327. PubMed ID: 36122798
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibility.
Lee NY; Hum M; Amali AA; Lim WK; Wong M; Myint MK; Tay RJ; Ong PY; Samol J; Lim CW; Ang P; Tan MH; Lee SC; Lee ASG
Hum Genomics; 2022 Nov; 16(1):61. PubMed ID: 36424660
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing in 51 early onset non-familial CRC cases.
Thutkawkorapin J; Lindblom A; Tham E
Mol Genet Genomic Med; 2019 May; 7(5):e605. PubMed ID: 30809968
[TBL] [Abstract][Full Text] [Related]
14. Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer.
Wen H; Kim YC; Snyder C; Xiao F; Fleissner EA; Becirovic D; Luo J; Downs B; Sherman S; Cowan KH; Lynch HT; Wang SM
BMC Cancer; 2014 Jun; 14():470. PubMed ID: 24969172
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort.
Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A
Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
Gracia-Aznarez FJ; Fernandez V; Pita G; Peterlongo P; Dominguez O; de la Hoya M; Duran M; Osorio A; Moreno L; Gonzalez-Neira A; Rosa-Rosa JM; Sinilnikova O; Mazoyer S; Hopper J; Lazaro C; Southey M; Odefrey F; Manoukian S; Catucci I; Caldes T; Lynch HT; Hilbers FS; van Asperen CJ; Vasen HF; Goldgar D; Radice P; Devilee P; Benitez J
PLoS One; 2013; 8(2):e55681. PubMed ID: 23409019
[TBL] [Abstract][Full Text] [Related]
18. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
[TBL] [Abstract][Full Text] [Related]
19. The spectrum of mutations predisposing to familial breast cancer in Poland.
Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Rusak B; Stempa K; Gronwald J; Szymiczek A; Bagherzadeh M; Jakubowska A; Dębniak T; Lener M; Rudnicka H; Szwiec M; Jarkiewicz-Tretyn J; Stawicka M; Domagała P; Narod SA; Lubiński J; Akbari MR;
Int J Cancer; 2019 Dec; 145(12):3311-3320. PubMed ID: 31173646
[TBL] [Abstract][Full Text] [Related]
20. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
Fierheller CT; Guitton-Sert L; Alenezi WM; Revil T; Oros KK; Gao Y; Bedard K; Arcand SL; Serruya C; Behl S; Meunier L; Fleury H; Fewings E; Subramanian DN; Nadaf J; Bruce JP; Bell R; Provencher D; Foulkes WD; El Haffaf Z; Mes-Masson AM; Majewski J; Pugh TJ; Tischkowitz M; James PA; Campbell IG; Greenwood CMT; Ragoussis J; Masson JY; Tonin PN
Genome Med; 2021 Dec; 13(1):186. PubMed ID: 34861889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
